Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib in FGFR-amplified metastatic breast cancer
NCT04024436Phase 2Terminated
- Sponsor
- Taiho Oncology
- Start
- Jan 2020
- Primary completion
- May 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 2, open-label trial of futibatinib in breast cancer (4 cohorts), sponsored by Taiho Oncology. Primary endpoints: Objective Response Rate, Clinical Benefit Rate and 1 more. Started Jan 2020; status: terminated.
02
Drugs
futibatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04024436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024436.